Clinical trial
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III…
NCT00331630 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00331630 |
|---|---|
| Title | Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer |
| Official title | Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib) |
| Lead sponsor | Northwestern University, Other |
| Collaborators | GlaxoSmithKline Industry Celgene Corporation |
| Status | Completed |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | lapatinib ditosylate, paclitaxel albumin-stabilized nanoparticle formulation |
| Enrollment | 30 |
| Start date | May 4, 2006 |
| Primary completion | Nov 10, 2006 |
| Completion | Aug 5, 2010 |
| First posted | May 31, 2006 |
| Last update posted | Mar 6, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: